# Turn Therapeutics Inc.: financial statements, quarterly

TTRX · Nasdaq · CIK 2023016 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ttrx.md) · [Financials](/companies/ttrx/financials.md) · [Filings](/companies/ttrx/filings.md) · [Insiders](/companies/ttrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ttrx/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [153](/filings/0001213900-25-109586.md) | [9.8 d](/filings/0001213900-26-037505.md) | [9.3](/filings/0001213900-26-054490.md) | [62.7](/filings/0001213900-26-088427.md) | [159](/filings/0001213900-25-109586.md) | [34.9 d](/filings/0001213900-26-037505.md) | [109](/filings/0001213900-26-054490.md) | [475](/filings/0001213900-26-088427.md) |
| Operating income | $k | [(673)](/filings/0001213900-25-109586.md) | [(329) d](/filings/0001213900-26-037505.md) | [(385)](/filings/0001213900-26-054490.md) | [(1,367)](/filings/0001213900-26-088427.md) | [(1,914)](/filings/0001213900-25-109586.md) | [(2,194) d](/filings/0001213900-26-037505.md) | [(1,246)](/filings/0001213900-26-054490.md) | [(1,628)](/filings/0001213900-26-088427.md) |
| Net income | $k | [(666)](/filings/0001213900-25-109586.md) | [(323) d](/filings/0001213900-26-037505.md) | [(329)](/filings/0001213900-26-054490.md) | [(1,240)](/filings/0001213900-26-088427.md) | [(1,904)](/filings/0001213900-25-109586.md) | [279 d](/filings/0001213900-26-037505.md) | [(971)](/filings/0001213900-26-054490.md) | [(5,850)](/filings/0001213900-26-088427.md) |
| Diluted EPS | $ per share | [(0.03)](/filings/0001213900-25-109586.md) | not reported | [(0.01)](/filings/0001213900-26-054490.md) | [(0.05)](/filings/0001213900-26-088427.md) | [(0.07)](/filings/0001213900-25-109586.md) | not reported | [(0.03)](/filings/0001213900-26-054490.md) | [(0.20)](/filings/0001213900-26-088427.md) |
| Basic EPS | $ per share | [(0.03)](/filings/0001213900-25-109586.md) | not reported | [(0.01)](/filings/0001213900-26-054490.md) | [(0.05)](/filings/0001213900-26-088427.md) | [(0.07)](/filings/0001213900-25-109586.md) | not reported | [(0.03)](/filings/0001213900-26-054490.md) | [(0.20)](/filings/0001213900-26-088427.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [0.5](/filings/0001213900-25-109586.md) | [0.5](/filings/0001213900-26-037505.md) | not reported | not reported | [0.5](/filings/0001213900-25-109586.md) | [4.0](/filings/0001213900-26-088427.md) | [11.0](/filings/0001213900-26-054490.md) | [9.9](/filings/0001213900-26-088427.md) |
| Current assets | $m | not reported | not reported | [1.1](/filings/0001213900-26-037505.md) | not reported | not reported | [3.3](/filings/0001213900-25-109586.md) | [5.2](/filings/0001213900-26-088427.md) | [11.5](/filings/0001213900-26-054490.md) | [10.4](/filings/0001213900-26-088427.md) |
| Total assets | $m | not reported | not reported | [2.0](/filings/0001213900-26-037505.md) | not reported | not reported | [4.3](/filings/0001213900-25-109586.md) | [12.2](/filings/0001213900-26-088427.md) | [18.6](/filings/0001213900-26-054490.md) | [17.0](/filings/0001213900-26-088427.md) |
| Current liabilities | $m | not reported | not reported | [0.7](/filings/0001213900-26-037505.md) | not reported | not reported | [2.3](/filings/0001213900-25-109586.md) | [6.0](/filings/0001213900-26-088427.md) | [5.1](/filings/0001213900-26-054490.md) | [8.8](/filings/0001213900-26-088427.md) |
| Total liabilities | $m | not reported | not reported | [2.2](/filings/0001213900-26-037505.md) | not reported | not reported | [3.8](/filings/0001213900-25-109586.md) | [7.5](/filings/0001213900-26-088427.md) | [12.5](/filings/0001213900-26-054490.md) | [16.3](/filings/0001213900-26-088427.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [5.9](/filings/0001213900-26-054490.md) | [6.1](/filings/0001213900-26-088427.md) |
| Shareholders' equity | $m | [0.1](/filings/0001213900-26-037505.md) | [(0.4)](/filings/0001213900-25-109586.md) | [(0.2)](/filings/0001213900-26-088427.md) | [0.8](/filings/0001213900-26-054490.md) | [1.8](/filings/0001213900-26-088427.md) | [0.5](/filings/0001213900-25-109586.md) | [4.7](/filings/0001213900-26-088427.md) | [6.1](/filings/0001213900-26-054490.md) | [0.7](/filings/0001213900-26-088427.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(431) d](/filings/0001213900-26-037505.md) | [(298)](/filings/0001213900-26-054490.md) | [(500) d](/filings/0001213900-26-088427.md) | [(589) d](/filings/0001213900-25-109586.md) | [(1,176) d](/filings/0001213900-26-037505.md) | [(1,633)](/filings/0001213900-26-054490.md) | [(923) d](/filings/0001213900-26-088427.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities

## Shares

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [26.6](/filings/0001213900-25-109586.md) | [27.0](/filings/0001213900-26-054490.md) | [27.5](/filings/0001213900-26-088427.md) | [28.0](/filings/0001213900-25-109586.md) | [29.5](/filings/0001213900-26-054490.md) | [29.8](/filings/0001213900-26-088427.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 29,788,040 at 2026-08-12, from the cover of the [10-Q filed 2026-08-12](/filings/0001213900-26-088427.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.